Detalles de la búsqueda
1.
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Lancet Oncol;
25(1): 29-45, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101433
2.
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Lancet Oncol;
25(1): 46-61, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101431
3.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet;
395(10236): 1547-1557, 2020 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416780
4.
Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer.
Int J Gynecol Cancer;
26(2): 261-7, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26807562
5.
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.
Cell Rep Med;
5(2): 101393, 2024 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280376
6.
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Eur Urol Open Sci;
58: 28-36, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954037
Resultados
1 -
6
de 6
1
Próxima >
>>